{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:32:21Z","timestamp":1794061941098,"version":"4.8.0"},"reference-count":162,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To review immune checkpoint inhibitor indications and ophthalmic side effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A literature review was performed using a PubMed search for publications between 1990 and 2017.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Immune checkpoint inhibitors are designed to treat system malignancies by targeting one of three ligands, leading to T-cell activation for attack against malignant cells. These ligands (and targeted drug) include cytotoxic T-lymphocyte antigen-4 (CTLA-4, ipilimumab), programmed death protein 1 (PD-1, pembrolizumab, nivolumab), and programmed death ligand-1 (PD-L1, atezolizumab, avelumab, durvalumab). These medications upregulate the immune system and cause autoimmune-like side effects. Ophthalmic side effects most frequently manifest as uveitis (1%) and dry eye (1\u201324%). Other side effects include myasthenia gravis (n = 19 reports), inflammatory orbitopathy (n = 11), keratitis (n = 3), cranial nerve palsy (n = 3), optic neuropathy (n = 2), serous retinal detachment (n = 2), extraocular muscle myopathy (n = 1), atypical chorioretinal lesions (n = 1), immune retinopathy (n = 1), and neuroretinitis (n = 1). Most inflammatory side effects are managed with topical or periocular corticosteroids, but advanced cases require systemic corticosteroids and cessation of checkpoint inhibitor therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Checkpoint inhibitors enhance the immune system by releasing inhibition on T cells, with risk of autoimmune-like side effects. Ophthalmologists should include immune-related adverse events in their differential when examining cancer patients with new ocular symptoms.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000002181","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T15:55:36Z","timestamp":1524585336000},"page":"1063-1078","source":"Crossref","is-referenced-by-count":321,"title":["CHECKPOINT INHIBITOR IMMUNE THERAPY"],"prefix":"10.1097","volume":"38","author":[{"given":"Lauren A.","family":"Dalvin","sequence":"first","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania"},{"name":"Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota ; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol L.","family":"Shields","sequence":"additional","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlana","family":"Orloff","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takami","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Shields","sequence":"additional","affiliation":[{"name":"Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"Immunotargets Ther"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/ajco.12698","article-title":"Immune checkpoint inhibitors: navigating a new paradigm of treatment toxicities","volume":"13","author":"Roberts","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1634\/theoncologist.13-S4-2","article-title":"The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation","volume":"13","author":"Wolchok","year":"2008","journal-title":"Oncologist"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.2174\/1381612823666171004120152","article-title":"PD-1\/PD-L1 inhibitors for immuno-oncology: from antibodies to small molecules","volume":"23","author":"Geng","year":"2017","journal-title":"Curr Pharm Des"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Science"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nm1517","article-title":"Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma","volume":"13","author":"Parsa","year":"2007","journal-title":"Nat Med"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-08-1608","article-title":"Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma","volume":"15","author":"Gao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.autrev.2015.12.001","article-title":"The autoimmune diseases of the eyes","volume":"15","author":"de Andrade","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3410\/B2-3","article-title":"Ocular immune privilege","volume":"2","author":"Zhou","year":"2010","journal-title":"F1000 Biol Rep"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3109\/08820538.2015.1114849","article-title":"New translational research in the medical management of orbital melanoma","volume":"31","author":"Dagi Glass","year":"2016","journal-title":"Semin Ophthalmol"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/IOP.0000000000000075","article-title":"Cutaneous melanoma metastatic to the orbit: review of 15 cases","volume":"30","author":"Greene","year":"2014","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1097\/IOP.0000000000000790","article-title":"Immune checkpoint inhibitors for treatment of metastatic melanoma of the orbit and ocular adnexa","volume":"33","author":"Ford","year":"2017","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R22-20230816","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3928\/23258160-20160419-17","article-title":"Choroidal metastases from cutaneous melanoma","volume":"47","author":"Mercado","year":"2016","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/17469899.2014.921119","article-title":"Management of conjunctival malignant melanoma: a review and update","volume":"9","author":"Wong","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaophthalmol.2017.2279","article-title":"Pembrolizumab for recurrent conjunctival melanoma","volume":"135","author":"Kini","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ctrv.2017.08.009","article-title":"Immune checkpoint blockade for unresectable or metastatic uveal melanoma: a systematic review","volume":"60","author":"Heppt","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes","volume":"127","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R28-20230816","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/j.ophtha.2017.04.003","article-title":"Personalized prognosis of uveal melanoma based on cytogenetic profile in 1059 patients over an 8-year period: the 2017 Harry S. Gradle Lecture","volume":"124","author":"Shields","year":"2017","journal-title":"Ophthalmology"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ophtha.2016.12.026","article-title":"Cytogenetic abnormalities in uveal melanoma based on tumor features and size in 1059 patients: the 2016 W. Richard Green Lecture","volume":"124","author":"Shields","year":"2017","journal-title":"Ophthalmology"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11912-017-0606-5","article-title":"Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies","volume":"19","author":"Komatsubara","year":"2017","journal-title":"Curr Oncol Rep"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3109\/0284186X.2013.786839","article-title":"Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)","volume":"52","author":"Kelderman","year":"2013","journal-title":"Acta Oncol"},{"key":"R33-20230816","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-naive patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PLoS One"},{"key":"R34-20230816","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00262-011-1089-0","article-title":"Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy","volume":"61","author":"Danielli","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/CMR.0000000000000125","article-title":"The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma","volume":"25","author":"Moser","year":"2015","journal-title":"Melanoma Res"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2 study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"e1143997","DOI":"10.1080\/2162402X.2016.1143997","article-title":"Clinical activity and safety of pembrolizumab in ipilimumab pre-treated patients with uveal melanoma","volume":"5","author":"Karydis","year":"2016","journal-title":"Oncoimmunology"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CMR.0000000000000242","article-title":"The use of pembrolizumab for the treatment of metastatic uveal melanoma","volume":"26","author":"Kottschade","year":"2016","journal-title":"Melanoma Res"},{"key":"R39-20230816","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/cam4.887","article-title":"Anti-PD-1 antibodies in metastatic uveal melanoma: a treatment option?","volume":"6","author":"Bender","year":"2017","journal-title":"Cancer Med"},{"key":"R40-20230816","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/0284186X.2016.1260773","article-title":"Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands","volume":"56","author":"van der Kooij","year":"2017","journal-title":"Acta Oncol"},{"key":"R41-20230816","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.05.038","article-title":"Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1\/cytotoxic T-lymphocyte antigen-4 inhibition","volume":"82","author":"Heppt","year":"2017","journal-title":"Eur J Cancer"},{"key":"R42-20230816","doi-asserted-by":"crossref","first-page":"9541","DOI":"10.1200\/JCO.2016.34.15_suppl.9541","article-title":"Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma","volume":"34","author":"Javed","year":"2016","journal-title":"J Clin Oncol"},{"key":"R43-20230816","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"R44-20230816","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1200\/JCO.2012.41.6750","article-title":"Management of immune-related adverse events and kinetics of response with ipilimumab","volume":"30","author":"Weber","year":"2012","journal-title":"J Clin Oncol"},{"key":"R45-20230816","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/14737140.2017.1296765","article-title":"Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review","volume":"17","author":"Abdel-Rahman","year":"2017","journal-title":"Expert Rev Anticancer Ther"},{"key":"R46-20230816","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/CCO.0000000000000296","article-title":"Ocular and orbital side-effects of checkpoint inhibitors: a review article","volume":"28","author":"Antoun","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"R47-20230816","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.soncn.2017.08.003","article-title":"Cancer therapy with checkpoint inhibitors: establishing a role for ophthalmology","volume":"33","author":"Davis","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"R48-20230816","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer"},{"key":"R49-20230816","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/CJI.0000000000000161","article-title":"Myasthenia gravis after nivolumab therapy for squamous cell carcinoma of the bladder","volume":"40","author":"Chang","year":"2017","journal-title":"J Immunother"},{"key":"R50-20230816","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.nmd.2017.01.002","article-title":"Myasthenia triggered by immune checkpoint inhibitors: new case and literature review","volume":"27","author":"Gonzalez","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"R51-20230816","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2217\/imt-2017-0043","article-title":"Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review","volume":"9","author":"Hasegawa","year":"2017","journal-title":"Immunotherapy"},{"key":"R52-20230816","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1200\/JCO.2013.51.1683","article-title":"Myasthenia gravis induced by ipilimumab in patients with metastatic melanoma","volume":"33","author":"Johnson","year":"2015","journal-title":"J Clin Oncol"},{"key":"R53-20230816","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1111\/cas.12961","article-title":"Myasthenic crisis and polymyositis induced by one dose of nivolumab","volume":"107","author":"Kimura","year":"2016","journal-title":"Cancer Sci"},{"key":"R54-20230816","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/mus.24648","article-title":"Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer","volume":"52","author":"Loochtan","year":"2015","journal-title":"Muscle Nerve"},{"key":"R55-20230816","first-page":"11","article-title":"Myasthenia gravis and rhabdomyolysis in a patient with advanced renal cell cancer treated with nivolumab: a case report and review of the literature","volume":"2","author":"Lopez","year":"2015","journal-title":"Br J Med Health Res"},{"key":"R56-20230816","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25163","article-title":"Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer","volume":"54","author":"Polat","year":"2016","journal-title":"Muscle Nerve"},{"key":"R57-20230816","first-page":"548","article-title":"Myasthenia gravis induced by ipilimumab in a patient with advanced melanoma","volume":"23","author":"Montes","year":"2016","journal-title":"Eur J Neurol"},{"key":"R58-20230816","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/01658107.2017.1291686","article-title":"A case report of drug-induced myopathy involving extraocular muscles after combination therapy with tremelimumab and durvalumab for non-small cell lung cancer","volume":"41","author":"Carrera","year":"2017","journal-title":"Neuroophthalmology"},{"key":"R59-20230816","doi-asserted-by":"crossref","first-page":"S155","DOI":"10.1097\/IOP.0000000000000509","article-title":"Inflammatory orbitopathy associated with ipilimumab","volume":"33","author":"Sheldon","year":"2017","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R60-20230816","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1097\/IOP.0000000000000081","article-title":"A case report of orbital inflammatory syndrome secondary to ipilimumab","volume":"31","author":"Henderson","year":"2015","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R61-20230816","first-page":"140","article-title":"Ipilimumab-induced ocular and orbital inflammation\u2013a case series and review of the literature","volume":"24","author":"Papavasileiou","year":"2016","journal-title":"Ocul Immunol Inflamm"},{"key":"R62-20230816","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/art.38282","article-title":"Drug-associated polymyalgia rheumatica\/giant cell arteritis occurring in two patients after treatment with ipilimumab, an antagonist of ctla-4","volume":"66","author":"Goldstein","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R63-20230816","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/1346-8138.13779","article-title":"Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: a case report","volume":"45","author":"Numata","year":"2017","journal-title":"J Dermatol"},{"key":"R64-20230816","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer"},{"key":"R65-20230816","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/ICO.0000000000000724","article-title":"Cyclosporine for dry eye associated with nivolumab: a case progressing to corneal perforation","volume":"35","author":"Nguyen","year":"2016","journal-title":"Cornea"},{"key":"R66-20230816","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/acr.23177","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"R67-20230816","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1158\/2326-6066.CIR-14-0053","article-title":"Bevacizumab plus ipilimumab in patients with metastatic melanoma","volume":"2","author":"Hodi","year":"2014","journal-title":"Cancer Immunol Res"},{"key":"R68-20230816","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/annrheumdis-2016-209595","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R69-20230816","doi-asserted-by":"crossref","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network","volume":"8","author":"Voskens","year":"2013","journal-title":"PLoS One"},{"key":"R70-20230816","first-page":"8","article-title":"Bilateral uveitis and keratitis following nivolumab treatment for metastatic melanoma","volume":"3","author":"Baughman","year":"2017","journal-title":"Med Case Rep (Wilmington)"},{"key":"R71-20230816","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.lungcan.2016.10.008","article-title":"Corneal graft rejection in a patient treated with nivolumab for primary lung cancer","volume":"102","author":"Le Fournis","year":"2016","journal-title":"Lung Cancer"},{"key":"R72-20230816","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1200\/JCO.2011.41.4359","article-title":"Anti-cytotoxic T-cell lymphocyte antigen-4-induced regression of spinal cord metastases in association with renal failure, atypical pneumonia, vision loss, and hearing loss","volume":"30","author":"Voskens","year":"2012","journal-title":"J Clin Oncol"},{"key":"R73-20230816","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12348-016-0082-3","article-title":"Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma","volume":"6","author":"Hahn","year":"2016","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"R74-20230816","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1097\/WNO.0000000000000217","article-title":"Ipilimumab-associated bilateral optic neuropathy","volume":"35","author":"Yeh","year":"2015","journal-title":"J Neuroophthalmol"},{"key":"R75-20230816","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40425-016-0170-9","article-title":"Acute visual loss after ipilimumab treatment for metastatic melanoma","volume":"4","author":"Wilson","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R76-20230816","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000448730","article-title":"In vivo confocal microscopy in differentiating ipilimumab-induced anterior uveitis from metastatic uveal melanoma","volume":"7","author":"Kiratli","year":"2016","journal-title":"Case Rep Ophthalmol"},{"key":"R77-20230816","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.6004\/jnccn.2014.0105","article-title":"Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash","volume":"12","author":"Nallapaneni","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"key":"R78-20230816","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.jcjo.2014.10.010","article-title":"New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient","volume":"50","author":"Miserocchi","year":"2015","journal-title":"Can J Ophthalmol"},{"key":"R79-20230816","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J Immunother"},{"key":"R80-20230816","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.1016\/j.jcjo.2015.09.008","article-title":"Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report","volume":"51","author":"Basilious","year":"2016","journal-title":"Can J Ophthalmol"},{"key":"R81-20230816","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/art.39406","article-title":"Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment","volume":"68","author":"de Velasco","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R82-20230816","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/09273948.2016.1215473","article-title":"Bilateral anterior uveitis associated with nivolumab therapy","volume":"26","author":"Karlin","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"key":"R83-20230816","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jiac.2017.04.007","article-title":"Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient","volume":"23","author":"Kanno","year":"2017","journal-title":"J Infect Chemother"},{"key":"R84-20230816","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/pcmr.12607","article-title":"A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity","volume":"30","author":"Chan","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"R85-20230816","first-page":"1183","article-title":"Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report","volume":"10","author":"Richardson","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"R86-20230816","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00002371-200411000-00008","article-title":"Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis","volume":"27","author":"Robinson","year":"2004","journal-title":"J Immunother"},{"key":"R87-20230816","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.5301\/ejo.5000724","article-title":"A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab","volume":"26","author":"Abu Samra","year":"2016","journal-title":"Eur J Ophthalmol"},{"key":"R88-20230816","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/ICB.0000000000000368","article-title":"Pembrolizumab administration associated with posterior uveitis","volume":"11","author":"Aaberg","year":"2017","journal-title":"Retin Cases Brief Rep"},{"key":"R89-20230816","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/CJI.0000000000000143","article-title":"Pembrolizumab-triggered uveitis: an additional surrogate marker for responders in melanoma immunotherapy?","volume":"39","author":"Diem","year":"2016","journal-title":"J Immunother"},{"key":"R90-20230816","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1002\/phar.1839","article-title":"A rare case of pembrolizumab-induced uveitis in a patient with metastatic melanoma","volume":"36","author":"Hanna","year":"2016","journal-title":"Pharmacotherapy"},{"key":"R91-20230816","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ajoc.2016.04.004","article-title":"A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy","volume":"2","author":"Taylor","year":"2016","journal-title":"Am J Ophthalmol Case Rep"},{"key":"R92-20230816","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1055\/s-0042-102668","article-title":"Intraocular inflammation associated with new therapies for cutaneous melanoma\u2014case series and review","volume":"233","author":"Fierz","year":"2016","journal-title":"Klin Monbl Augenheilkd"},{"key":"R93-20230816","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40425-014-0041-1","article-title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","volume":"2","author":"Manusow","year":"2014","journal-title":"J Immunother Cancer"},{"key":"R94-20230816","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1001\/jamaophthalmol.2015.1128","article-title":"Detachments during ipilimumab treatment for cutaneous melanoma","volume":"133","author":"Mantopoulos","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R95-20230816","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3928\/23258160-20150610-10","article-title":"Ipilimumab-associated retinopathy","volume":"46","author":"Crews","year":"2015","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"R96-20230816","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jamaophthalmol.2017.4872","article-title":"Combination ipilimumab and nivolumab for metastatic melanoma associated with ciliochoroidal effusion and exudative retinal detachment","volume":"135","author":"Tsui","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R97-20230816","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1001\/jamaophthalmol.2016.2944","article-title":"Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab","volume":"134","author":"Roberts","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"R98-20230816","article-title":"Immune retinopathy associated with nivolumab administration for metastatic non-small cell lung cancer","author":"Reddy","year":"2017","journal-title":"Retin Cases Brief Rep"},{"key":"R99-20230816","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/ICB.0b013e31824f7130","article-title":"Bilateral drug (ipilimumab)-induced vitritis, choroiditis, and serous retinal detachments suggestive of Vogt-Koyanagi-Harada syndrome","volume":"6","author":"Wong","year":"2012","journal-title":"Retin Cases Brief Rep"},{"key":"R100-20230816","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/1346-8138.13612","article-title":"Case of acute anterior uveitis and Vogt-Koyanagi-Harada syndrome-like eruptions induced by nivolumab in a melanoma patient","volume":"44","author":"Arai","year":"2017","journal-title":"J Dermatol"},{"key":"R101-20230816","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/ccr3.911","article-title":"Vogt-Koyanagi-Harada disease-like posterior uveitis in the course of nivolumab (anti-PD-1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma","volume":"5","author":"Matsuo","year":"2017","journal-title":"Clin Case Rep"},{"key":"R102-20230816","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3109\/15569527.2013.781618","article-title":"Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma","volume":"32","author":"Modjtahedi","year":"2013","journal-title":"Cutan Ocul Toxicol"},{"key":"R103-20230816","article-title":"Bilateral metastatic cutaneous melanoma to retina and vitreous after ipilimumab treated with pars plana vitrectomy and radiotherapy","author":"Kanavati","year":"2016","journal-title":"Retin Cases Brief Rep"},{"key":"R104-20230816","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ajo.2013.09.019","article-title":"Autoimmune retinopathy","volume":"157","author":"Grange","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R105-20230816","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.survophthal.2012.02.004","article-title":"Paraneoplastic vitelliform retinopathy: clinicopathologic correlation and review of the literature","volume":"57","author":"Aronow","year":"2012","journal-title":"Surv Ophthalmol"},{"key":"R106-20230816","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1167\/tvst.4.3.2","article-title":"Nonantibestrophin anti-RPE antibodies in paraneoplastic exudative polymorphous vitelliform maculopathy","volume":"4","author":"Dalvin","year":"2015","journal-title":"Transl Vis Sci Technol"},{"key":"R107-20230816","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R108-20230816","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","article-title":"Nivolumab and ipilimumab versus ipilimumab in untreated melanoma","volume":"372","author":"Postow","year":"2015","journal-title":"N Engl J Med"},{"key":"R109-20230816","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"R110-20230816","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"R111-20230816","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1158\/1078-0432.CCR-11-1823","article-title":"CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma","volume":"18","author":"Prieto","year":"2012","journal-title":"Clin Cancer Res"},{"key":"R112-20230816","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"key":"R113-20230816","first-page":"9","article-title":"Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials","volume":"10","author":"Wolchok","year":"2010","journal-title":"Cancer Immun"},{"key":"R114-20230816","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"R115-20230816","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1470-2045(16)00175-3","article-title":"Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial","volume":"17","author":"Muro","year":"2016","journal-title":"Lancet Oncol"},{"key":"R116-20230816","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for platinum- and cetuximab-refractory head and neck cancer: results from a single-arm, phase II study","volume":"35","author":"Bauml","year":"2017","journal-title":"J Clin Oncol"},{"key":"R117-20230816","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"R118-20230816","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N Engl J Med"},{"key":"R119-20230816","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1200\/JCO.2015.64.0391","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","journal-title":"J Clin Oncol"},{"key":"R120-20230816","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"key":"R121-20230816","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"R122-20230816","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R123-20230816","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"R124-20230816","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"R125-20230816","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"R126-20230816","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"R127-20230816","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"R128-20230816","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"R129-20230816","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"R130-20230816","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"R131-20230816","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"key":"R132-20230816","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R133-20230816","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"R134-20230816","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R135-20230816","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"R136-20230816","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"R137-20230816","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"R138-20230816","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R139-20230816","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1200\/JCO.2014.58.3708","article-title":"Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer","volume":"33","author":"Gettinger","year":"2015","journal-title":"J Clin Oncol"},{"key":"R140-20230816","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"R141-20230816","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"R142-20230816","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"R143-20230816","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"R144-20230816","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"R145-20230816","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"R146-20230816","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"R147-20230816","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"R148-20230816","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"key":"R149-20230816","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial Bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"R150-20230816","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan Kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"R151-20230816","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.08.005","article-title":"PD-1 checkpoint inhibition: toxicities and management","author":"Hahn","year":"2017","journal-title":"Urol Oncol"},{"key":"R152-20230816","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/neuonc\/nou001","article-title":"Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma","volume":"16","author":"Liao","year":"2014","journal-title":"Neuro Oncol"},{"key":"R153-20230816","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/IOP.0b013e3181ef72a1","article-title":"Drug-induced Graves disease from CTLA-4 receptor suppression","volume":"27","author":"Borodic","year":"2011","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R154-20230816","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/IOP.0b013e3182895795","article-title":"Re: \u201cDrug-induced Graves disease from CTLA-4 receptor suppression.\u201d","volume":"29","author":"Sohrab","year":"2013","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"R155-20230816","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"R156-20230816","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/01676830.2014.949792","article-title":"Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab","volume":"33","author":"McElnea","year":"2014","journal-title":"Orbit"},{"key":"R157-20230816","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"R158-20230816","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"R159-20230816","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/1078155216687389","article-title":"Pembrolizumab-induced myasthenia gravis: a fatal case report","volume":"24","author":"March","year":"2017","journal-title":"J Oncol Pharm Pract"},{"key":"R160-20230816","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/CMR.0000000000000310","article-title":"Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients","volume":"27","author":"Nguyen","year":"2017","journal-title":"Melanoma Res"},{"key":"R161-20230816","doi-asserted-by":"crossref","first-page":"E25","DOI":"10.1002\/mus.25496","article-title":"A case of new-onset antibody-positive myasthenia gravis in a patient treated with pembrolizumab for melanoma","volume":"55","author":"Alnahhas","year":"2017","journal-title":"Muscle Nerve"},{"key":"R162-20230816","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"R163-20230816","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1158\/1078-0432.CCR-14-2468","article-title":"Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma","volume":"21","author":"Gibney","year":"2015","journal-title":"Clin Cancer Res"},{"key":"R164-20230816","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1158\/2326-6066.CIR-15-0193","article-title":"Phase I\/II study of metastatic melanoma patients treated with nivolumab who had progressed after ipilimumab","volume":"4","author":"Weber","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"R165-20230816","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/mus.25212","article-title":"Benign form of myasthenia gravis after nivolumab treatment","volume":"54","author":"Sciacca","year":"2016","journal-title":"Muscle Nerve"},{"key":"R166-20230816","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jjco\/hyv158","article-title":"Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma","volume":"46","author":"Shirai","year":"2016","journal-title":"Jpn J Clin Oncol"},{"key":"R167-20230816","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"R168-20230816","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S1470-2045(15)00544-6","article-title":"Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006982-201806000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:28:06Z","timestamp":1692232086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006982-201806000-00001"}},"subtitle":["Systemic Indications and Ophthalmic Side Effects"],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":162,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000002181","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}